EP3727362A4 - Promédicaments lipidiques d'acide mycophénolique et leurs utilisations - Google Patents

Promédicaments lipidiques d'acide mycophénolique et leurs utilisations Download PDF

Info

Publication number
EP3727362A4
EP3727362A4 EP18890811.5A EP18890811A EP3727362A4 EP 3727362 A4 EP3727362 A4 EP 3727362A4 EP 18890811 A EP18890811 A EP 18890811A EP 3727362 A4 EP3727362 A4 EP 3727362A4
Authority
EP
European Patent Office
Prior art keywords
mycophenolic acid
medicinal products
acid lipid
lipid medicinal
products
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP18890811.5A
Other languages
German (de)
English (en)
Other versions
EP3727362A1 (fr
Inventor
Daniel Kenneth BONNER
Ketki KARANAM
Sifei HAN
Luojuan HU
Christopher John Hamilton Porter
Tim QUACH
Rishab R. SHYAM
Jamie SIMPSON
Natalie TREVASKIS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Seaport Therapeutics Inc
Monash University
Original Assignee
Monash University
Puretech LYT Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Monash University, Puretech LYT Inc filed Critical Monash University
Publication of EP3727362A1 publication Critical patent/EP3727362A1/fr
Publication of EP3727362A4 publication Critical patent/EP3727362A4/fr
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542Carboxylic acids, e.g. a fatty acid or an amino acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87Benzo [c] furans; Hydrogenated benzo [c] furans
    • C07D307/88Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP18890811.5A 2017-12-19 2018-12-19 Promédicaments lipidiques d'acide mycophénolique et leurs utilisations Pending EP3727362A4 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762607749P 2017-12-19 2017-12-19
US201862724274P 2018-08-29 2018-08-29
US201862768583P 2018-11-16 2018-11-16
PCT/US2018/066585 WO2019126378A1 (fr) 2017-12-19 2018-12-19 Promédicaments lipidiques d'acide mycophénolique et leurs utilisations

Publications (2)

Publication Number Publication Date
EP3727362A1 EP3727362A1 (fr) 2020-10-28
EP3727362A4 true EP3727362A4 (fr) 2021-10-06

Family

ID=66994291

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18890811.5A Pending EP3727362A4 (fr) 2017-12-19 2018-12-19 Promédicaments lipidiques d'acide mycophénolique et leurs utilisations

Country Status (2)

Country Link
EP (1) EP3727362A4 (fr)
WO (1) WO2019126378A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11883497B2 (en) 2017-08-29 2024-01-30 Puretech Lyt, Inc. Lymphatic system-directing lipid prodrugs
EP3675838A4 (fr) 2017-08-29 2021-04-21 PureTech LYT, Inc. Promédicaments lipidiques orientant vers le système lymphatique
CN109851593B (zh) * 2019-02-01 2021-04-16 沈阳药科大学 基于淋巴介导转运的甘油三酯前药及其制备方法
US12569438B2 (en) 2019-07-29 2026-03-10 Georgia Tech Research Corporation Nanomaterials containing constrained lipids and uses thereof
JP7699128B2 (ja) * 2019-12-06 2025-06-26 ガイド セラピューティクス,エルエルシー ナノマテリアル
US12435035B2 (en) 2020-01-09 2025-10-07 Guide Therapeutics, Llc Nanomaterials
IL303845A (en) 2021-01-20 2023-08-01 Beam Therapeutics Inc Nanomaterials include a degradable property
WO2024019936A1 (fr) 2022-07-20 2024-01-25 Beam Therapeutics Inc. Nanomatériaux comprenant des triols
CN120983421A (zh) * 2025-09-08 2025-11-21 齐鲁工业大学(山东省科学院) 霉酚酸甲酯在制备抗血栓药物中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017041139A1 (fr) * 2015-09-08 2017-03-16 Monash University Promédicaments ciblant la lymphe
WO2019046491A1 (fr) * 2017-08-29 2019-03-07 Ariya Therapeutics, Inc. Promédicaments lipidiques orientant vers le système lymphatique

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6013665A (en) 1997-12-16 2000-01-11 Abbott Laboratories Method for enhancing the absorption and transport of lipid soluble compounds using structured glycerides
EP1389617B1 (fr) 2001-04-27 2007-01-03 Zenyaku Kogyo Kabushiki Kaisha Compose heterocyclique et agent antitumoral contenant ce dernier en tant qu'ingredient actif
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
WO2004019973A1 (fr) 2002-08-14 2004-03-11 Atugen Ag Nouvelle mise en application de la proteine kinase n beta
KR20070087266A (ko) 2003-04-03 2007-08-28 세마포르 파머슈티컬즈, 아이엔씨. 피아이-3 키나아제 억제제 프로드러그
CN1832939B (zh) 2003-05-30 2010-04-28 杰明X医药品加拿大公司 用于治疗癌症或病毒病的三杂环化合物、组合物和方法
US7173015B2 (en) 2003-07-03 2007-02-06 The Trustees Of The University Of Pennsylvania Inhibition of Syk kinase expression
SI2612862T1 (sl) 2004-05-13 2017-04-26 Icos Corporation Kinazolini kot inhibitorji humane fosfatidilinozitol 3-kinaze delta
DE602006010979D1 (de) 2005-01-19 2010-01-21 Rigel Pharmaceuticals Inc Prodrugs aus 2,4-pyrimidindiamin-verbindungen und ihre verwendungen
EP1888550B1 (fr) 2005-05-12 2014-06-25 AbbVie Bahamas Ltd. Promoteurs d'apoptose
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
US7402325B2 (en) 2005-07-28 2008-07-22 Phoenix Biotechnology, Inc. Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander
BRPI0617162B8 (pt) 2005-10-07 2021-05-25 Exelixis Inc compostos inibidores de fosfatidilinositol 3-quinase composições farmacêuticas que os contem e métodos de uso dos mesmos
CN103626742B (zh) 2005-11-01 2017-04-26 塔格根公司 激酶的联-芳基间-嘧啶抑制剂
EP2455382B1 (fr) 2005-12-13 2016-10-26 Incyte Holdings Corporation Pyrrolo[2,3-b]pyridines et pyrrolo[2,3-b]pyrimidines à substitution hétéroaryle en tant qu'inhibiteurs de la janus kinase
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
US20090023805A1 (en) * 2006-02-13 2009-01-22 Anne Claire Marrast Method of administration
MX2008013578A (es) 2006-04-26 2009-03-23 Hoffmann La Roche Derivados de tieno [3,2-d]pirimidina utiles como inhibidores de fosfatidilinositol 3-cinasa(p13k).
WO2008012246A1 (fr) 2006-07-24 2008-01-31 Basf Se Azolylméthyloxiranes, leur utilisation dans la lutte contre des champignons phytopathogènes et agents les contenant
BRPI0622054B8 (pt) 2006-09-22 2021-05-25 Oxford Amherst Llc composto e composição farmacêutica
HRP20151386T1 (hr) 2007-03-12 2016-02-26 Ym Biosciences Australia Pty Ltd Fenil aminopirimidinski spojevi i njihova primjena
WO2008118802A1 (fr) 2007-03-23 2008-10-02 Regents Of The University Of Minnesota Composés thérapeutiques
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
KR100975520B1 (ko) 2008-02-01 2010-08-12 종근당바이오 주식회사 마이코페놀레이트 모페틸의 개선된 제조방법
US8158616B2 (en) 2008-03-11 2012-04-17 Incyte Corporation Azetidine and cyclobutane derivatives as JAK inhibitors
KR101698028B1 (ko) 2008-05-20 2017-01-26 노이로제스엑스, 인코포레이티드 수용성 아세트아미노펜 유사체
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
WO2011051967A2 (fr) * 2009-10-23 2011-05-05 Alkem Laboratories Ltd Compositions pharmaceutiques contenant du mycophénolate et leurs procédés de préparation
US20110213028A1 (en) * 2010-02-26 2011-09-01 Catabasis Pharmaceuticals, Inc. Fatty acid mycophenolate derivatives and their uses
EP4578865A3 (fr) 2014-08-12 2025-07-30 Monash University Promédicaments dirigeant la lymphe

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017041139A1 (fr) * 2015-09-08 2017-03-16 Monash University Promédicaments ciblant la lymphe
WO2019046491A1 (fr) * 2017-08-29 2019-03-07 Ariya Therapeutics, Inc. Promédicaments lipidiques orientant vers le système lymphatique
EP3675838A1 (fr) * 2017-08-29 2020-07-08 Puretecch LYT, Inc. Promédicaments lipidiques orientant vers le système lymphatique

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2019126378A1 *

Also Published As

Publication number Publication date
WO2019126378A1 (fr) 2019-06-27
EP3727362A1 (fr) 2020-10-28

Similar Documents

Publication Publication Date Title
EP3727362A4 (fr) Promédicaments lipidiques d'acide mycophénolique et leurs utilisations
EP3478693A4 (fr) Dérivés d'acide boronique et leurs utilisations thérapeutiques
MA53650A (fr) Lipides peg et leurs utilisations
MA53652A (fr) Lipides peg de haute pureté et leurs utilisations
EP3817769A4 (fr) Anticorps anti-cd47 humains et leurs utilisations
EP3891183A4 (fr) Anticorps anti-claudine et leurs utilisations
EP3759143A4 (fr) Anticorps anti-tigit et leurs utilisations
EP3625263A4 (fr) Anticorps anti-galectine-9 et leurs utilisations
EP3720502A4 (fr) Produits cytobiologiques et leurs utilisations thérapeutiques
EP3370770A4 (fr) Formulations sous-cutanée d'anticorps anti-cd38 et leurs utilisations
MA47789A (fr) Anticorps anti-phf-tau et leurs utilisations
EP3481430A4 (fr) Conjugués de type acide nucléique et leurs utilisations
EP3475449A4 (fr) Étalons d'acide nucléique acellulaire et leurs utilisations
EP3518971A4 (fr) Formulations thérapeutiques d'anticorps et de protéines et leurs utilisations
MA49886A (fr) Anticorps anti-par2 et leurs utilisations
EP3681912A4 (fr) Anticorps spécifiques d'axl et leurs utilisations
MA45125A (fr) Anticorps anti-alpha-synucléine et leurs utilisations
EP3555076A4 (fr) Nouveaux dérivés de l'acide phényl propionique et leurs utilisations
EP3645563A4 (fr) Anticorps anti-fam19a5 et leurs utilisations
EP3790586A4 (fr) Anticorps anti-dll3 et leurs utilisations
EP3672987A4 (fr) Anticorps anti-apéline et leurs utilisations
EP3380525A4 (fr) Formulations pharmaceutiques et leurs procédés d'utilisation
EP3850012A4 (fr) Anticorps anti-tnfrsf9 et leurs utilisations
EP3755714A4 (fr) Anticorps anti-angiopoïétine-2 et leurs utilisations
EP3894440A4 (fr) Anticorps anti-il-27 et leurs utilisations

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20200717

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20210902

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20220614

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0031138000

Ipc: A61K0045060000

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0045060000

Ipc: A61K0047540000

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 307/88 20060101ALI20241009BHEP

Ipc: A61K 47/54 20170101ALI20241009BHEP

Ipc: A61K 45/06 20060101AFI20241009BHEP

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 19/02 20060101ALI20241011BHEP

Ipc: A61P 25/00 20060101ALI20241011BHEP

Ipc: A61P 1/00 20060101ALI20241011BHEP

Ipc: A61P 37/06 20060101ALI20241011BHEP

Ipc: A61P 37/00 20060101ALI20241011BHEP

Ipc: C07D 307/88 20060101ALI20241011BHEP

Ipc: A61K 45/06 20060101ALI20241011BHEP

Ipc: A61K 47/54 20170101AFI20241011BHEP

INTG Intention to grant announced

Effective date: 20241029

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: MONASH UNIVERSITY

Owner name: SEAPORT THERAPEUTICS, INC.

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTC Intention to grant announced (deleted)
RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: MONASH UNIVERSITY

Owner name: SEAPORT THERAPEUTICS, INC.

INTG Intention to grant announced

Effective date: 20250318

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTC Intention to grant announced (deleted)
INTG Intention to grant announced

Effective date: 20250804

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

INTC Intention to grant announced (deleted)
GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20260129